The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
暂无分享,去创建一个
B. Levine | C. June | A. Maity | J. Plastaras | S. Lacey | A. Cohen | M. Milone | E. Stadtmauer | A. Garfall | J. Melenhorst | Joshua Jones | S. Manjunath | Megan M. Davis | R. Maxwell | W. Arscott | I. Paydar | M. Davis
[1] B. Lei,et al. Chimeric Antigen Receptor T Cell Therapy in the Relapsed or Refractory Multiple Myeloma with Extramedullary Disease--a Single Institution Observation in China , 2020, Blood.
[2] S. Jagannath,et al. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma , 2020 .
[3] M. V. D. van den Brink,et al. T cell regeneration after immunological injury , 2020, Nature Reviews Immunology.
[4] C. Robert,et al. Can radiation-recall predict long lasting response to immune checkpoint inhibitors? , 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[5] Michael L. Wang,et al. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. , 2020, Blood advances.
[6] S. Jagannath,et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. , 2020 .
[7] Ying Xiao,et al. Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma. , 2020, International journal of radiation oncology, biology, physics.
[8] S. Jagannath,et al. Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. , 2020 .
[9] Aaron D. Falchook,et al. Radiation therapy as a bridging strategy for CAR T cell therapy with axicabtagene ciloleucel in diffuse large B-cell lymphoma. , 2019, International journal of radiation oncology, biology, physics.
[10] Wei-Ting Hwang,et al. T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. , 2019, Blood advances.
[11] He Huang,et al. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[12] A. Goldberg,et al. BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy , 2019, Cancer Immunology Research.
[13] Weiss,et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. , 2019, The Journal of clinical investigation.
[14] Wei-ping Chen,et al. Impact of radiotherapy on immunological parameters, levels of inflammatory factors, and clinical prognosis in patients with esophageal cancer , 2019, Journal of radiation research.
[15] K. Tobinai,et al. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges , 2019, Drugs in context.
[16] H. Goldschmidt,et al. Navigating the treatment landscape in multiple myeloma: which combinations to use and when? , 2018, Annals of Hematology.
[17] Michael L. Wang,et al. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] K. Davis,et al. Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.
[19] P. Sonneveld. Management of multiple myeloma in the relapsed/refractory patient. , 2017, Hematology. American Society of Hematology. Education Program.
[20] H. Lokhorst,et al. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update , 2017, Drugs.
[21] Daniel Li,et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. , 2017, Blood.
[22] M. Weller,et al. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma , 2017, Clinical Cancer Research.
[23] K. Anderson,et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond , 2017, Leukemia.
[24] A. Minn,et al. Radiation and Immune Checkpoint Blockade: From Bench to Clinic. , 2017, Seminars in radiation oncology.
[25] S. Heimfeld,et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells , 2016, Science Translational Medicine.
[26] C. June,et al. Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy , 2016, Clinical Cancer Research.
[27] David L. Porter,et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia , 2015, Science Translational Medicine.
[28] Pamela A Shaw,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.
[29] Qing He,et al. Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.
[30] K. Schäkel,et al. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.
[31] H. Goldschmidt,et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study , 2012, Leukemia.
[32] Michel Sadelain,et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.
[33] S. Rosenberg,et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. O'Hara,et al. Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART). , 2007, Translational lung cancer research.
[35] K. Camphausen,et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006, The Journal of experimental medicine.
[36] M. Weller,et al. NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. , 2018, Cancer research.
[37] J. Renau‐Piqueras,et al. Extramedullary multiple myeloma , 1982, Virchows Archiv. B, Cell pathology including molecular pathology.